Clinical Trials

Celldex CDX0159-10 Research Study for Prurigo Nodularis (PN) – Clinical Trial

If you or someone you know suffers from Prurigo Nodularis (PN), a chronic skin condition causing firm, itchy nodules, you may be eligible to participate in a clinical research study evaluating an investigational treatment, barzolvolimab.

The study will last approximately 11 months (44 weeks), including screening, treatment, and follow-up periods. Participants will receive the investigational treatment or a placebo and will be monitored through 13 in-person visits to the study site. A daily e-diary via a smartphone app will also be part of the study.

Study Criteria:

Male or female, aged 18 and older
Have a clinical diagnosis of prurigo nodularis
Tried and failed prescription topical medications for PN
Experience severe itching due to PN
Participation is at no cost, and compensation for time and travel may be available.

For more information, please visit: barzolPNstudy.com

This study is actively enrolling.

People aged 18 and above if diagnosed with plaque psoriasis (PSO) have an opportunity to participate in a research trial run by study-doctors who specialize in treating psoriasis. Participation will be for around 32 weeks, involving 13 visits to the research site, and does not cost anything to participate or receive treatment.

• Double blind, vehicle-controlled Phase IIb study to assess the safety and efficacy of topically applied DS107 cream in mild to moderate atopic dermatitis
• Phase 3 confirmatory study investigating efficacy and safety of dupilumab monotherapy in adults with moderate to severe atopic dermatitis
• Phase 3 double blind, placebo-controlled study investigating the efficacy and safety of multiple Dupilumab dose regimens for maintaining response in patients with atopic dermatitis
• Open label study of Dupilumab in patients with atopic dermatitis
• Tralokinumab monotherapy for adults with moderate to severe atopic dermatitis
• Double blind, placebo-controlled study to evaluate the efficacy and safety of Barictinib in adults with moderate to severe atopic dermatitis
• Open label, phase 3 study to evaluate efficacy and safety of Bariticinib in adults with moderate to severe atopic dermatitis

• Canadian Humira post-marketing observational epidemiological study assessing effectiveness in psoriasis
• Phase 3 study to evaluate the efficacy and safety of Brodalumab compared with placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis
• Open label study to assess the safety of Etanercept in subjects with plaque psoriasis
• Risankizumab versus placebo in patients with moderate to severe plaque psoriasis
• Double blind study of Secukinumab to demonstrate efficacy compared to Ustekinumab in subjects with moderate to severe plaque psoriasis
• Double blind, active-control study to compare efficacy and safety of CHS-1420 versus Humira in subjects with chronic plaque psoriasis
• Double blind study assessing short and long term efficacy, safety and tolerability of Secukinumab in subjects of body weight 90 kg or higher with moderate to severe plaque psoriasis
• A Phase 3 Efficacy and safety study of Taparinof for the treatment of plaque psoriasis in adults
• A Phase 3, Multicenter, Randomized, Double Blind Study Evaluating the Efficacy and Safety of ABP654 Compared with Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis
• A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy,Safety, and Immunogenicity of Multiple Switches Between Humira®(adalimumab [US]) and ABP 501 Compared With Continued Use of Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis

• Phase 3 Double-blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib cream Followed by an Extension period in Participants with Vitiligo
• A Double-blind, Vehicle-controlled Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo

Recruiting adults aged 18 to 64 for a clinical trial investigating reducing subcutaneous abdominal fat. Eligible participants must have a stable body weight of 50 kg or greater (less than 3 kg weight change in the past 3 months), with a body mass between 18.5 and 27 kg/m2. Participants must maintain a stable lifestyle for at least 3 months (e.g., exercise, eating patterns, and smoking habits) and not have poorly controlled diabetes within the past 6 months (requiring a change in glucose control medications other than day-to-day insulin requirement variations). A participant should not have a fear of injections or needles (or faints at the sight of blood or needles), not have folding fat or skin while standing, and not have tattoos on the front and/or lateral side of the abdomen. Participants will receive either an investigational injection treatment (study drug) or a placebo. Study treatment and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided. Study participation will last about 25 weeks and involve about 9 visits to the study center. If you would like to participate or want to learn more, please contact our clinical trials coordinator.

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata